Standard BioTools (LAB) awards 500,000 RSUs to chief business officer

Rhea-AI Filing Summary

Mackay Sean reported acquisition or exercise transactions in this Form 4 filing.

STANDARD BIOTOOLS INC. reported that SVP & Chief Business Officer Sean Mackay received a grant of 500,000 shares of Common Stock in the form of restricted stock units. These RSUs were granted at no cash cost and increase his direct holdings to 1,506,552 shares after the award.

The RSUs vest over time based on continued service: 40% will vest on June 20, 2027 and the remaining 60% will vest on June 20, 2028, so Mackay receives the underlying shares only if he remains with the company through those dates.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mackay Sean

Role SVP & Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	500,000	$0.00	--

Holdings After Transaction: Common Stock — 1,506,552 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 500,000 shares Post-transaction holdings: 1,506,552 shares Vesting on June 20, 2027: 40% of RSUs +2 more

5 metrics

RSUs granted 500,000 shares Restricted stock units awarded to Sean Mackay

Post-transaction holdings 1,506,552 shares Total Common Stock held directly after grant

Vesting on June 20, 2027 40% of RSUs First vesting tranche subject to continued service

Vesting on June 20, 2028 60% of RSUs Second vesting tranche subject to continued service

Grant price $0.0000 per share RSUs granted at no cash cost

Key Terms

restricted stock units, RSUs, vesting, continued service, +1 more

5 terms

restricted stock units financial

"Represents restricted stock units ("RSUs"), 40% of which will vest on June 20, 2027"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"Represents restricted stock units ("RSUs"), 40% of which will vest on June 20, 2027"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

vesting financial

"40% of which will vest on June 20, 2027, and the remaining 60% of which will vest on June 20, 2028"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continued service financial

"will vest on June 20, 2028 subject to the Reporting Person's continued service to the Company"

common stock financial

"Each RSU represents the right to receive one share of common stock upon vesting."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 05:45 PM Accepted by SEC EDGAR 06/23/2026 - 05:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mackay Sean

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

50 MILK STREET, 10TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2026		A		500,000(1)	A	$0	1,506,552	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs"), 40% of which will vest on June 20, 2027, and the remaining 60% of which will vest on June 20, 2028 subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Each RSU represents the right to receive one share of common stock upon vesting.

	/s/ Sean Mackay by Tomone Tanaka, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did STANDARD BIOTOOLS (LAB) report for Sean Mackay?

STANDARD BIOTOOLS reported that SVP & Chief Business Officer Sean Mackay received 500,000 restricted stock units. These RSUs are a stock-based compensation award, not an open-market purchase or sale, and were granted at no cash cost to Mackay.

How many shares did Sean Mackay hold after this Form 4 transaction at STANDARD BIOTOOLS (LAB)?

After the RSU grant, Sean Mackay held 1,506,552 shares of Common Stock directly. This total includes the 500,000 restricted stock units reported in the filing, which convert into common shares only as they vest over the specified dates.

How do the 500,000 RSUs granted to Sean Mackay at STANDARD BIOTOOLS (LAB) vest?

The 500,000 RSUs vest in two tranches tied to continued service. Forty percent vest on June 20, 2027, and the remaining 60% vest on June 20, 2028, provided Sean Mackay continues serving the company through each vesting date.

Are the 500,000 RSUs to Sean Mackay at STANDARD BIOTOOLS (LAB) an open-market stock purchase?

No, the 500,000 shares reported are restricted stock units granted as compensation. Each RSU represents the right to receive one share of common stock upon vesting, rather than shares bought by Mackay in the open market.

What does each RSU granted to Sean Mackay by STANDARD BIOTOOLS (LAB) represent?

Each restricted stock unit represents the right to receive one share of STANDARD BIOTOOLS common stock when it vests. The award delivers shares over time, contingent on Sean Mackay’s continued service to the company through the vesting dates.